Related Experiment Video
Updated: Jul 11, 2026
07:51
The Application of 1% Methylene Blue Dye As a Single Technique in Breast Cancer Sentinel Node Biopsy
Published on: June 1, 2019
Sentinel lymph node biopsy in cutaneous melanoma: a case-control study.
Ilkka Koskivuo1, Lauri Talve, Pia Vihinen
1Department of Surgery, Turku University Hospital, P.O. Box 52, FIN-20521, Turku, Finland. ilkka.koskivuo@tyks.fi
Annals of Surgical Oncology
|October 10, 2007
Summary
Sentinel lymph node biopsy (SLNB) improves regional disease control in cutaneous melanoma patients. SLNB provides crucial prognostic information for melanoma survival, supporting its routine use in treatment.
Area of Science:
- Oncology
- Dermatology
- Surgical Pathology
Background:
- Sentinel lymph node biopsy (SLNB) is the most accurate method for staging invasive cutaneous melanoma.
- Its therapeutic impact remains challenging to evaluate, limiting routine adoption in all treatment centers.
Purpose of the Study:
- To assess the therapeutic effect and prognostic value of SLNB in cutaneous melanoma.
- To compare outcomes between patients who underwent SLNB and those who did not.
Main Methods:
- A case-control study involving 305 prospective SLNB patients and 616 retrospective non-SLNB patients.
- Inclusion of thin melanomas in both study groups for comprehensive analysis.
Main Results:
- Sentinel lymph node biopsy identified 16.4% of patients as sentinel positive.
- Completion lymph node dissection revealed additional metastases in 18% of sentinel-positive cases.
- SLNB demonstrated a significant difference in melanoma-related overall survival (OS) and improved nodal disease-free survival.
Conclusions:
- SLNB is recommended for routine cutaneous melanoma treatment due to its unique prognostic information.
- The sentinel node status significantly impacts melanoma patient survival.
- SLNB combined with immediate completion lymph node dissection offers improved regional disease control.
